ZGPAT
(Zinc Finger, CCCH-Type with G Patch Domain (ZGPAT))
Épitope
C-Term
Reactivité
Humain
Hôte
Poulet
Clonalité
Polyclonal
Conjugué
Cet anticorp ZGPAT est non-conjugé
Application
Western Blotting (WB), ELISA, Immunofluorescence (IF)
Specificité
Multiple isoforms of ZGPAT are known to exist.
Purification
ZGPAT Antibody is affinity chromatography purified via peptide column.
Immunogène
ZGPAT antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human ZGPAT. The immunogen is located within the last 50 amino acids of ZGPAT.
ZGPAT antibody can be used for detection of ZGPAT by Western blot at 1 μ,g/mL. Antibody can also be used for immunofluorescence starting at 20 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
ZGPAT Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
ZGPAT antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
ZGPAT
(Zinc Finger, CCCH-Type with G Patch Domain (ZGPAT))
ZGPAT Antibody: The Zinc finger CCCH-type with G patch domain-containing protein (ZGPAT), is a transcriptional repressor that regulates several cellular pathways including EGFR pathways that are involved in cell proliferation, migration and survival. ZGPAT recruits the Mi-2/NuRD complex and represses the expression of EGFR. ZGPAT is down-regulated in breast carcinomas and its expression is negatively correlated with that of EGFR, suggesting that it may be a potential target for breast cancer therapy. Multiple isoforms of ZGPAT are known to exist, including sZIP, which binds to the Mi-2/NuRD complex but lacks the DNA binding component of full-length ZGPAT, thereby antagonizing transcription repression and growth inhibition by ZGPAT.